A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate
Esophageal Neoplasms
DRUG: Apatinib|DRUG: The chemotherapeutic drug chosen by the investigator.
PFS, progression-free survival, One year from admission
OS, Overall Survival, One year from admission|DCR, disease control rate, One year from admission|ORR, Objective Response Rate, One year from admission
This is a randomized, open-label, multi-center, phase II clinical trial initiated by a investigator to observe and evaluate the efficacy of apatinib in the treatment of patients with failed first-line treatment after recurrence and metastasis of esophageal squamous cell carcinoma. Effectiveness and security.